Anika Therapeutics, Inc. (ANIK)

NASDAQ: ANIK · Real-Time Price · USD
17.33
-0.54 (-3.02%)
Dec 12, 2024, 4:00 PM EST - Market closed
-3.02%
Market Cap 253.81M
Revenue (ttm) 164.17M
Net Income (ttm) -97.52M
Shares Out 14.65M
EPS (ttm) -6.62
PE Ratio n/a
Forward PE 41.26
Dividend n/a
Ex-Dividend Date n/a
Volume 90,401
Open 17.87
Previous Close 17.87
Day's Range 17.19 - 18.17
52-Week Range 16.00 - 29.12
Beta 0.90
Analysts Buy
Price Target 24.50 (+41.37%)
Earnings Date Oct 31, 2024

About ANIK

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from... [Read more]

Sector Healthcare
IPO Date Apr 29, 1993
Employees 357
Stock Exchange NASDAQ
Ticker Symbol ANIK
Full Company Profile

Financial Performance

In 2023, Anika Therapeutics's revenue was $166.66 million, an increase of 6.67% compared to the previous year's $156.24 million. Losses were -$82.67 million, 456.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 41.37% from the latest price.

Price Target
$24.5
(41.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Anika To Participate in December 2024 Investor Conferences

BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management...

20 days ago - GlobeNewsWire

Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - Presiden...

5 weeks ago - Seeking Alpha

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoratio...

6 weeks ago - PRNewsWire

Anika Reports Third Quarter 2024 Financial Results

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwin...

6 weeks ago - GlobeNewsWire

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitab...

6 weeks ago - GlobeNewsWire

Anika Announces Third Quarter 2024 Results Conference Call Date

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...

2 months ago - GlobeNewsWire

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 202...

2 months ago - GlobeNewsWire

Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript

Anika Therapeutics, Inc (NASDAQ:ANIK) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Ex...

4 months ago - Seeking Alpha

Anika Reports Second Quarter 2024 Financial Results

Expanded Regenerative Solutions portfolio with full market release of the Integrity™  Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating signif...

4 months ago - GlobeNewsWire

Anika to Participate in the Sidoti Virtual Investor Conference

BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will p...

4 months ago - GlobeNewsWire

Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024

BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...

5 months ago - GlobeNewsWire

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio

5 months ago - GlobeNewsWire

Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research

Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerati...

5 months ago - GlobeNewsWire

Anika Enters into Cooperation Agreement with Caligan Partners

Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program

7 months ago - GlobeNewsWire

Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communicati...

7 months ago - Seeking Alpha

Anika Announces CFO Transition

Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024

7 months ago - GlobeNewsWire

Anika Reports First Quarter 2024 Financial Results

Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million,...

7 months ago - GlobeNewsWire

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plan...

8 months ago - GlobeNewsWire

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will ...

9 months ago - GlobeNewsWire

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reductio...

9 months ago - GlobeNewsWire

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024

BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...

10 months ago - GlobeNewsWire

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS

10 months ago - GlobeNewsWire

Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release

Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio

1 year ago - GlobeNewsWire

Anika to Participate in Upcoming Investor Conferences

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanch...

1 year ago - GlobeNewsWire